If management can fund R&D/operations through licensing for the next 12-18 months and avoid CR, I'll be very happy.
It says something that the company's commercial strategy begun with solving the manufacturing issues for EVs, rather than developing a drug for another 'unmet need'. Smart. Most small biotechs don't have the clout to get anywhere - hoping EX1 is different.
Does anyone here have a solid understanding of EX1's patent portfolio?
Ann: Letter to Shareholders, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
